<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="696">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>26/09/2005</approvaldate>
  <actrnumber>ACTRN12605000505606</actrnumber>
  <trial_identification>
    <studytitle>The STEAL Study</studytitle>
    <scientifictitle>A randomised, open-label trial to assess the safety and efficacy of switching to tenofovir-emtricitabine or abacavir-lamivudine in HIV: The STEAL study.</scientifictitle>
    <utrn />
    <trialacronym>STEAL</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Combination antiretroviral therapy for the treatment of HIV has a high pill burden.  Two dual-tablets, abacavir-lamivudine and tenofovir-emtricitabine, are now licensed in the United States and will be available in Australia in December 2005.  Data available suggest that the potency of these tablets are similar in controlling replication of the HIV virus, but not have not been directly compared in regard to clinically significant toxicities.  We therefore aim to compare the overall safety and efficacy of the two dual-tablets over a 2 year period in HIV infected adults.  We hypothesise that the two dual-NRTI treatments will be similar in efficacy and safety.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Virological failure defined by HIV RNA &gt; 400 copies/mL plasma on two consecutive occasions greater than or equal to 4 weeks apart (Roche Amplicor version 1.5, LLD 50 copies/mL)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. plasma HIV RNA &lt;50 copies/mL</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. time to virological failure</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. virological resistance in those with virological failure </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. all serious adverse events, regardless of causality</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. clinical adverse events (all grades and grade 3-4), regardless of causality</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. use of concomitant medications for toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7. adherence (clinician assessed)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8. quality of life (SF-8)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>9. CD4+ lymphocyte count</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>10. full blood count</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>11. biochemistry</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>12. lipid parameters</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>13. glycaemic parameters</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>14. DEXA parameters</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>15. non-traumatic bone fractures</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>16. resolution of adverse events (e.g. dyslipidaemia, low BMD, diabetes)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>17. progression to AIDS (Category C)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>18. death</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>19. discontinuation of any ART component</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. documented HIV infection2. age at least 18 years3. stable (greater than or equal to 12 weeks) ART including at least two NRTIs, currently well tolerated, with no plan to change any other component of the ART regimen at or after baseline4. HIV RNA &lt; 50 copies/mL plasma for the preceding 12 weeks5. GFR greater than or equal to 70 mL/min/1.73m2 (estimated by the abbreviated MDRD equation23estimated GFR = 186 x ([SCR/88.4]-1.154) x age-0.203 x (0.742 if female) x (1.210 if African-American)6. provision of written, informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. HLA-B57*01 positive at or prior to screening OR evidence of previous hypersensitivity or clinical failure with abacavir2. current therapy comprising triple NRTI therapy alone3. current use of ABC/3TC FDC (Kivexa) or TDF/FTC FDC (Truvada)4. pregnancy or breast feeding5. history of osteoporotic fracture6. prior hypersensitivity or intolerance to ABC, 3TC, TDF or FTC7. prior clinical failure to a regimen containing ABC or TDF8. prior use of TDF for control of previously active hepatitis B (HBsAg+ or HBV DNA+) in patients likely to be resistant to 3TC/FTC9. current therapy including unboosted atazanavir10. concurrent use of aminoglycosides, IV amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, probenecid, adefovir or immunomodulatory agents11. clinical evidence of cirrhosis (e.g. smooth liver, no features of portal hypertension)12. creatinine clearance &lt; 50 mL/min (estimated by the Cockcroft-Gault equation)Male: (140 - age in years) x (wt in kg) = CLCr (mL/min) 0.814 x (serum creatinine in Ã¿Âµmol/L)Female:(140 - age in years) x (wt in kg) x 0.85 = CLCr (mL/min) 0.814 x (serum creatinine in Ã¿Âµmol/L).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be randomised in a 1:1 ratio to one of two interventional arms.  The study is open-label.  The randomisation will be automatically performed via a computer program when the subject completes screening.  The computer program is part of an online case report form system accessed at all study sites.</concealment>
    <sequence>Computer generated. Subjects will be stratified by the type of NRTI they are currently taking (ABC, TDF or other); whether they are currently taking a protease inhibitor (yes or no); and by the site where they are randomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/12/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>350</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>The National Centre in HIV Epidemiology and Clinical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of New South Wales</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Combination antiretroviral therapy for the treatment of HIV has a high pill burden.  Two dual-tablets, abacavir-lamivudine and tenofovir-emtricitabine, are now licensed in the United States and will be available in Australia in December 2005.  Data available suggest that the potency of these tablets are similar in controlling replication of the HIV virus, but not have not been directly compared in regard to clinically significant toxicities.  We therefore aim to compare the overall safety and efficacy of the two dual-tablets over a 2 year period in HIV infected adults.  We hypothesise that the two dual-NRTI treatments will be similar in efficacy and safety.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Lismore Sexual Health Clinic.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Holdsworth House GP</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Burwood Road Practice.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. Vincents Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Taylor Square Private Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Albion Street Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>407 Doctors</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Health Service.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nambour Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Base Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Sexual Health Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>AIDS Medical Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gladstone Road Medical Centre,</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Care and Prevention Program, Adelaide University</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Sexual Health Centre.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Carlton Clinic.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prahran Market Clinic.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Centre Clinic.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Sean Emery</name>
      <address>National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 93850900</phone>
      <fax>+61 2 93850910</fax>
      <email>semery@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Allison Humphries</name>
      <address>National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 93850900</phone>
      <fax>+61 2 93850910</fax>
      <email>ahumphries@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>